THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.32] ID: TIP-MED-000160

Ivermectin & Diethylcarbamazine Citrate (DEC)

Active Ingredient / Scientific Identity: Ivermectin & Diethylcarbamazine Citrate • Class: Avermectin Glutamate-Gated Chloride Channel Agonist & Piperazine Antifilarial (Schedule H | NLEM 2022)

⚖️ Compare Profile
Generic / Entity NameIvermectin & Diethylcarbamazine Citrate (DEC) ([8.32])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassAvermectin Glutamate-Gated Chloride Channel Agonist & Piperazine Antifilarial (Schedule H
Available Dosage FormsIvermectin Tablets (Dispersible/Uncoated): 3 mg, 6 mg, 12 mg; Topical Cream: 1%. DEC Tablets: 50 mg, 100 mg; S
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Reduce DEC dose in moderate-to-severe CKD. Hepatic: Caution with Ivermectin in severe liver disease
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Ivermectin & Diethylcarbamazine Citrate (DEC) (TIP-MED-000160, Reference Code [8.32]) is classified under Antimicrobials — Antimalarial & Anthelmintic Agents (Ch 08) as a Avermectin Glutamate-Gated Chloride Channel Agonist & Piperazine Antifilarial (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.32], p. 108): Ivermectin: Ivecop (Menarini), Iverkem (Alkem), Vermact (Mankind); FDC: Bandy-Plus (Albendazole 400 mg + Ivermectin 6/12 mg). DEC: Hetrazan (Pfizer), Banocide / Banocide Forte (GSK) — Strengths & Dosage Forms: Ivermectin Tablets (Dispersible/Uncoated): 3 mg, 6 mg, 12 mg; Topical Cream: 1%. DEC Tablets: 50 mg, 100 mg; Syrup: 50 mg/5 mL, 120 mg/5 mL
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.32], p. 108): Ivermectin: Ivecop (Menarini), Iverkem (Alkem), Vermact (Mankind); FDC: Bandy-Plus (Albendazole 400 mg + Ivermectin 6/12 mg). DEC: Hetrazan (Pfizer), Banocide / Banocide Forte (GSK) — Strengths & Dosage Forms: Ivermectin Tablets (Dispersible/Uncoated): 3 mg, 6 mg, 12 mg; Topical Cream: 1%. DEC Tablets: 50 mg, 100 mg; Syrup: 50 mg/5 mL, 120 mg/5 mL
Dosage Forms & Available Strengths:
Ivermectin Tablets (Dispersible/Uncoated): 3 mg, 6 mg, 12 mg; Topical Cream: 1%. DEC Tablets: 50 mg, 100 mg; Syrup: 50 mg/5 mL, 120 mg/5 mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Avermectin Glutamate-Gated Chloride Channel Agonist & Piperazine Antifilarial (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Antimalarial & Anthelmintic Agents (Ch 08): clinical efficacy is mediated via Avermectin Glutamate-Gated Chloride Channel Agonist & Piperazine Antifilarial (Schedule H | NLEM 2022) for Ivermectin: Strongyloidiasis, crusted/refractory scabies (200 mcg/kg PO on Day 1 & Day 8–14 alongside topical Permethrin 5%), pediculosis capitis, cutaneous larva migrans. DEC: Lymphatic filariasis (Wuchereria bancrofti) and Tropical Pulmonary Eosinophilia (TPE — very common in India!).

4. Therapeutic Indications & Evidence-Supported Uses

  • Ivermectin: Strongyloidiasis, crusted/refractory scabies (200 mcg/kg PO on Day 1 & Day 8–14 alongside topical Permethrin 5%), pediculosis capitis, cutaneous larva migrans
  • DEC: Lymphatic filariasis (Wuchereria bancrofti) and Tropical Pulmonary Eosinophilia (TPE — very common in India!)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Ivermectin (Scabies / Strongyloidiasis): 200 mcg/kg PO as a single dose (typically 12 mg for a 60 kg adult); for Scabies, MUST repeat a second 200 mcg/kg dose on Day 8–14 (Ivermectin is NOT ovicidal!). DEC: Filariasis: 6 mg/kg/day in 3 divided doses (100 mg TDS) for 12 days; TPE: 6 mg/kg/day in 3 divided doses for 14–21 days

Administration & Meal Timing: Take Oral Ivermectin on an empty stomach with water. Take DEC immediately AFTER meals to minimise nausea | Ivermectin: Single dose on Day 1 & Day 8–14. DEC: Morning, Afternoon & Night (TDS) after meals

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Reduce DEC dose in moderate-to-severe CKD. Hepatic: Caution with Ivermectin in severe liver disease
Elimination & Renal Adjustment:
Renal: Reduce DEC dose in moderate-to-severe CKD. Hepatic: Caution with Ivermectin in severe liver disease
Hepatic Impairment Considerations:
Renal: Reduce DEC dose in moderate-to-severe CKD. Hepatic: Caution with Ivermectin in severe liver disease

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Ivermectin CONTRAINDICATED in children <15 kg (or <5 years — immature BBB allows GABA neurotoxicity!), pregnancy, and Loa loa co-infection. DEC CONTRAINDICATED in Onchocerciasis

Key Clinical Precautions: Renal: Reduce DEC dose in moderate-to-severe CKD. Hepatic: Caution with Ivermectin in severe liver disease

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Ivermectin: Transient exacerbation of pruritus in first 24–48h as mites die, mild dizziness, nausea. DEC: Fever, headache, myalgia, anorexia, arthralgia (immunological reaction to dying microfilariae in first 2–3 days — treat with Paracetamol & Antihistamines, do not stop DEC!)
  • Neurotoxicity/encephalopathy, ataxia, coma (in Ivermectin overdose, children <15 kg, or P-gp inhibitor co-administration)
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Strong P-gp inhibitors (Itraconazole, Ketoconazole, Cyclosporine, Verapamil) may increase CNS penetration of Ivermectin; monitor Warfarin INR

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: FOR SCABIES: Take the second Ivermectin tablet 7–14 days after the first tablet (to kill newly hatched mites), treat all household contacts simultaneously, and note that itching may persist for 1–2 weeks after mites are dead (use calamine/antihistamine, do not keep repeating Ivermectin daily!); FOR BANOCIDE/HETRAZAN: take after meals
  • Meal & Clock Timing Instruction: Take Oral Ivermectin on an empty stomach with water. Take DEC immediately AFTER meals to minimise nausea (Ivermectin: Single dose on Day 1 & Day 8–14. DEC: Morning, Afternoon & Night (TDS) after meals)
  • Missed Dose Protocol: Take DEC after next meal if missed; do not miss Day-8 repeat dose of Ivermectin in scabies
  • Geriatric Dispensing Pearl: Oral Ivermectin (200 mcg/kg Day 1 & Day 8) + Topical Permethrin 5% is highly effective for institutional/elderly crusted scabies

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ivermectin Tablets (Dispersible/Uncoated): 3 mg, 6 mg, 12 mg; Topical Cream: 1%. DEC Tablets: 50 mg, 100 mg; Syrup: 50 mg/5 mL, 120 mg/5 mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.32] (p. 108)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.